Tom Hardy

Company: Adipo Therapeutics

Job title: Chief Medical Officer

Bio:

Thomas Hardy, MD, PhD is Chief Medical Officer at Adipo Therapeutics. Dr. Hardy is an Endocrinologist with over 20 years of experience in clinical research and drug and medical device development. This includes 18 years at Eli Lilly and Company, where he held key roles working across all phases of clinical development in the Cardiometabolic Disease therapeutic area. While in Early Phase Medicine at Lilly, Dr. Hardy oversaw numerous IND filings and directed the design and implementation of over 30 phase 1 and 2 clinical trials of small and large molecule investigational agents across multiple disease areas. He subsequently directed the global registration trials and regulatory filings for late-phase assets in the Diabetes Business Unit, resulting in the global approvals of Baqsimi® and Lyumjev®. After working at Lilly, Dr. Hardy was the Head of Drug Safety and Pharmacovigilance at Immunovant. He holds an M.D. and Ph.D. (Biochemistry) from Indiana University and completed fellowship training in Diabetes, Endocrinology and Metabolism at Vanderbilt University Medical Center. Dr. Hardy has authored over 40 peer-reviewed publications.

Seminars:

Role of Notch-Inhibiting Nanoparticles in the Browning and Activation of White Adipose Tissue to Boost Resting Metabolic Rate and Increase Energy Expenditure 2:00 pm

Browning of white adipose tissue can be accomplished with Notch-inhibition which induces mitochondrial biogenesis and mitochondrial activation Notch-inhibiting NP have demonstrated weight loss and a decrease in blood glucose and lipids in rodents Human ex vivo fat studies support potential for clinical translation of Notch-inhibition in adults with obesity Minimal off-target impact and associated side…Read more

day: Pre-Conference Day